

0959-8049(95)00262-6

A Message From the New Editor-in-Chief

SITTING IN Henri Tagnon's office at the Institut Jules Bordet some 15 years ago, bargaining about the final acceptance of a revised paper on the first Swiss trial on adjuvant therapy of breast cancer, nobody would have predicted this frustrated author was ever to sit on the "other side" of the editorial table himself, probably causing similar agony to some of his colleagues in the future. However, to succeed Professor Henri Tagnon/Brussels, the Founder and Professor Michael Peckham, the Redesigner, as the third Editor-in-Chief of the European Journal of Cancer is both an honour and a challenge for me.

Having only recently been offered this position, I am prepared "to accept the ball" and to dedicate part of my future professional life to the further scientific evolution of the European Journal of Cancer. I am determined to see the European Journal of Cancer become a truly comprehensive, international oncology journal and forum of interdisciplinary scientific interaction of European oncologists with their colleagues from other parts of the world. This can be achieved only with your personal help and involvment as an innovative researcher and author, as a crucial and responsive reader and a faithful subscriber.

To approach this goal, some changes will take place to the Journal in the months to come: Experimental and translational

research in oncology, from "the bench to the bedside", will remain one of the cornerstones of the European Journal of Cancer, Ian Hart/London being responsible for this important section. New Associate Editors for the topics of Surgical Oncology (Peter Schlag/Berlin), Paediatric Oncology (Jon Pritchard/London) and Cancer in the Elderly or Geriatric Oncology (Silvio Monfardini/Aviano) have been appointed, whose role will be to develop the journal in these areas. In addition, the European Journal of Cancer is going "West" with the appointment of an American Associate Editor (Daniel Ihde/St Louis, Missouri, the former Editor-in-Chief of the Journal of the National Cancer Institute). Editorial procedures will be streamlined and there will be only one single port of entry for all manuscripts—the London Editorial Office at 33 Millman Street—with a permanent "hot wire" to St Gallen/Switzerland.

In closing, I would like to thank my predecessor, Professor Michael Peckham, the staff at the London Editorial Office (Dr Delphine Purves and Ms Sarah Hole) and also the representatives from Elsevier Science Ltd for their support during the initial phase of this new position for me.

Hans-Jörg Senn